Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.

ABSTRACT: Combination antiretroviral therapy (ART) is now the global standard for HIV-infected pregnant and breastfeeding women at all CD4? cell counts. We compared the efficacy and safety of an efavirenz versus lopinavir/ritonavir regimen for HIV-infected pregnant women initiating ART in rural Uganda.Randomized clinical trial.We performed a planned secondary analysis comparing viral load suppression (HIV-1 RNA ?400 copies/ml), safety, and HIV transmission to infants in a trial designed to test the hypothesis that lopinavir/ritonavir versus efavirenz-based ART would reduce placental malaria (PROMOTE, ClinicalTrials.gov, NCT00993031). HIV-infected, ART-naive pregnant women at 12-28 weeks gestation and any CD4? cell count were randomized. ART was provided and participants were counseled to breastfeed for 1 year postpartum.The median age of the 389 study participants was 29 years; median CD4? cell count was 370 cells/?l. At delivery, virologic suppression was 97.6% in the efavirenz arm and 86.0% in the lopinavir/ritonavir arm (P?

SUBMITTER: Cohan D 

PROVIDER: S-EPMC4428759 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature